BUTASYL 100ML | Non-steroidal anti-inflammatory-analgesic-antipyretic in injectable solution

BUTASYL

Non-steroidal anti-inflammatory-analgesic-antipyretic in injectable solution
Laboratory
PFIZER, SA
Pharmaceutical form
Injectable solution (Sol.i.)
Composition per ml:
Phenylbutazone (sodium salt) 200 mg; sodium salicylate 50 mg.
Pharmacological properties
Features: Non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic, antipyretic action
and anti-inflammatory.
Pharmacodynamic characteristics: The joint action of both compounds leads to an improvement
immediately in the animal due to the analgesic and antipyretic activity of sodium salicylate, followed by
due to the prolonged effect with greater anti-inflammatory activity of phenylbutazone.
Interactions and incompatibilities
None known.
Indications and target species
Equine: Acute inflammations (pneumonia, endocarditis, myocarditis). Arthritis of any
nature, analgesia, antipyrexia and rheumatism.
Contraindications
Animals with cardiorenal attacks, edema, gastritis and hemoglobinuria.
efectos secundarios
They have not been described.
Route of administration
Slow IV.
Posology
Equine: Adult animals: Initial dose: 20 ml/animal. Maintenance dose: 10 ml/animal.
foals: Initial dose: 10 ml/animal. Maintenance dose: 5 ml/animal. For 4-6 days in
function of the inflammatory process.
• During treatment, it is recommended to use a special hypoproteic diet,
decreasing the contribution of chlorides and administering massive amounts of vitamin C.
Special precautions
Do not administer to horses at least eight days before participating in a competition.
Wait time
Do not use in horses intended for human consumption.
conservation mode
Store in a refrigerator (between 2 – 8 °C).
Comments
With veterinary prescription.
Presentation
Bottle with 100 ml.
Reg No.
8.246

See technical sheet